HAIFA, Israel, April 16, 2014 (GLOBE NEWSWIRE) -- Pluristem Therapeutics, Inc. (Nasdaq:PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapies, announced today that Dr. Ohad Karnieli, Vice President of Development and Manufacturing, and Lena Pinzur, Basic and Preclinical Research Manager, will deliver presentations at the International Society for Cellular Therapy (ISCT) 2014 Conference which will take place in Paris, France on April 23 rd through 26 th, 2014. Additionally, Racheli Ofir, Vice President of Research & IP will be participating in ISCT's Industry Education Subcommittee. The ISCT is a global society of clinicians, regulators, technologists, and industry partners with a shared vision to translate cellular therapy into safe and effective treatments to improve patients' lives. Pluristem supports the advancement of cell therapy not only through its breakthrough technologies, but also through active participation in industry organizations like ISCT that play a key role in shaping the future of the industry.
Dr. Ohad Karnieli was recently confirmed as Chair of ISCT's Process and Product Committee for a two-year post.
"I am honored to serve as Chair of ISCT's Process and Product Committee. The committee acts as a leading force in the cell therapy industry by bringing together industry and academia to set standards and best practices that move cell therapy forward into commercialization for the benefit of patients. I look forward to making key contributions towards the committee's goals," stated Dr. Karnieli.Dr. Karnieli will co-chair a presentation and panel discussion with Dr. Knut Niss of Novartis titled, "Process and Product Development Innovation," during the Strategies for Commercialization track on April 26 th from 1:15 pm - 2:45 pm. On April 25 th from 5:00 pm - 6:30 pm, Ms. Pinzur will present a poster titled, "PLX-PAD Cell Treatment Mitigates Toll-Like Receptor Agonist-Induced Preeclampsia Symptoms in Mice." The research findings are based on pre-clinical studies conducted in conjunction with the Department of Internal Medicine, Division of Nephrology & Hypertension, Texas A&M Health Science Center and Scott & White Healthcare. Data from the study suggest that Pluristem's PLX-PAD cell treatment exerts beneficial effects by reducing inflammation and placental injury and demonstrate that PLX-PAD cells may be a potential novel therapeutic approach for the treatment of preeclampsia. About Pluristem Therapeutics Pluristem Therapeutics Inc. is a leading developer of placenta-based cell therapies. The Company's patented PLX (PLacental eXpanded) cells are a drug delivery platform that releases a cocktail of therapeutic proteins in response to a host of local and systemic inflammatory and ischemic diseases. PLX cells are grown using the company's proprietary 3D micro-environmental technology and are an "off-the-shelf" product that requires no tissue matching prior to administration.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts